Poseida Therapeutics Aktie: Potenzial wird voll ausgeschöpft!
Poseida Therapeutics verzeichnete im Jahr 2024 einen bemerkenswerten finanziellen Erfolg mit einem Jahresüberschuss von 1,4 Milliarden USD. Der Biotechnologiekonzern, der…
9,500$
-0,63%
Echtzeit-Aktienkurs Poseida Therapeutics
Bid:
Ask:
Nachrichten zur Poseida Therapeutics Aktie
Roche to complete acquisition of U.S. biopharma company Poseida
Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics via its subsidiary Blue…
Roche set to finalise $1.5bn Poseida Therapeutics takeover
Swiss healthcare firm Roche has said its US$1.5 billion takeover of US biopharmaceutical company Poseida Therapeutics will be completed on…
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash
Basel, 9 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for…
PBF Energy, Poseida Therapeutics, and More Stocks See Action From Activist Investors
…
Poseida Therapeutics Aktie: Tolle Perspektiven für Anleger!
Die Poseida Therapeutics Aktie verzeichnete im November 2024 eine bemerkenswerte Entwicklung an den Börsen. Mit einem aktuellen Kurs von 9,31…
Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet
The consensus price target hints at a 49.3% upside potential for Poseida Therapeutics (PSTX). While empirical research shows that this…
Poseida Therapeutics: What The Acquisition Offer Says About Big Pharma Priorities
…
Pharma-Deal: Roche baut Zelltherapie mit Übernahme von US-Biotechfirma aus
Der Schweizer Konzern will Poseida Therapeutics um bis zu 1,5 Milliarden Euro aufkaufen. Das kalifornische Unternehmen arbeitet unter anderem an Therapien…
Roche to acquire Poseida Therapeutics for $1.5bn
…
Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion
…
Roche to acquire US-based Poseida Therapeutics By Reuters
Roche to acquire US-based Poseida Therapeutics…
Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B
RHHBY is all set to acquire Poseida Therapeutics, Inc. and ramp up its pipeline with off-the-shelf cell therapies.…
Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
…